Tharisa PLC (THS:LSE) delivered a comprehensive investor presentation outlining its strategic transition from open-pit to underground mining, reinforcing its position as a vertically integrated, low-cost producer of platinum group metals (PGMs) and chrome. The company highlighted its phased underground expansion at the Apollo and Orion complexes, designed to extend the mine life by over 60 years, enhance operational efficiency, and secure multi-generational value creation. Early works are underway, with first ore expected from Apollo in FY2026 and steady-state production by FY2029, followed by Orion in FY2031.

The underground development will sustain output of over 200,000 ounces of PGMs and 2 million tonnes of chrome concentrate annually by 2033, while supporting ESG commitments, including a 30% carbon reduction target by 2030. With $832 million invested to date and $115 million returned to shareholders through dividends, Tharisa emphasized its disciplined capital allocation. The Apollo project carries a capex of $363 million, Orion $184 million, with peak funding of $173 million supported by bespoke financing facilities.

CEO Felli Peroulis stressed that underground mining mitigates long-term operational risks, improves ore quality, reduces waste, and maintains Tharisa’s lowest-cost quartile status. The transition also leverages smart mining technologies, mechanization, and sustainability-focused infrastructure to deliver safe, efficient operations. Alongside this flagship expansion, Tharisa is progressing its Karo Platinum project in Zimbabwe, positioning the group to double PGM production within five years.

With a projected post-tax NPV of $985 million at spot prices and strong fundamentals in both PGM and chrome markets, Tharisa PLC reinforced its commitment to shareholder returns, capital discipline, and community upliftment, while future-proofing operations through innovation, ESG stewardship, and resilient financial performance.

Microsalt PLC (SALT:AIM) delivered a strong H1 investor update, highlighting revenue growth to $800k, reduced net loss, and expanding global adoption of its patented low-sodium salt technology. The company’s breakthrough product delivers up to 50% less sodium without altering taste, positioning it as a compelling solution for global food manufacturers facing tightening health regulations. By mid-2025, Microsalt had already contributed to over 471 million servings, with full-year volumes expected to approach 1 billion. Growth is driven by increasing demand in the U.S., Mexico, Canada, and Europe, alongside new partnerships with multinational food producers. Operational efficiencies, scale advantages, and robust manufacturing capacity in the U.S. underpin improved margins and long-term profitability. Recognised with multiple industry awards, Microsalt continues to strengthen its competitive edge over potassium chloride substitutes, offering clean-label benefits and superior taste profiles. With a $37bn addressable salt market and strong momentum in high-visibility sectors such as snacks and quick-service restaurants, management forecasts sales of $6.7m in 2026 and over $11m in 2027, equating to nearly 3bn healthier servings annually. Backed by defensible IP, scalable production, and growing regulatory tailwinds, Microsalt positions itself as the leading partner for sodium reduction across the global food industry—driving revenue growth, margin expansion, and long-term shareholder value.

Dillistone Group PLC (DSG:AIM) delivered its Interim Results investor presentation highlighting resilient performance despite ongoing headwinds in the recruitment technology sector. Revenue declined 14% year-on-year, reflecting continued weakness in executive search demand, but adjusted EBITDA margins improved to 26.8% – nearly double 2021 levels – underscoring greater operational efficiency. The Group posted an adjusted operating profit of £79k versus a loss in 2021, supported by tighter cost control and stronger cash generation, with H1 2025 marking the highest operational cash flow in six years. While legacy FileFinder revenues continue to contract, management sees encouraging momentum in Talentis, its next-generation CRM and candidate sourcing platform. Talentis annual recurring revenue (ARR) grew 40% in Q3 alone, driven by a shift from short-term single-user licences to multi-user, long-term contracts, with clients now paying on average 30% more than on legacy products. Customer migrations, international adoption, and recent competitive wins support management’s confidence that Talentis can replace and surpass FileFinder as the Group’s flagship offering. Looking ahead, Dillistone expects lower churn, stronger new business orders, and a return to revenue growth in 2026, with potential for EBITDA margins to expand beyond 30% as Talentis scales. Despite a challenging UK recruitment market, the Group’s global footprint, recurring revenue model, and efficiency gains position it for sustainable growth. Investors were reassured that Dillistone has navigated the downturn, strengthened its balance sheet, and is now poised to capture market share through product innovation and international expansion.

Manx Financial Group PLC (MFX:AIM) delivered a strong interim performance for the six months to 30 June 2025, highlighting growth across its diversified financial services portfolio. Profit before tax rose 16% to £4.1m, with basic EPS up 50% year-on-year, reflecting improved margins, cost discipline, and strong contributions from Conister Bank, Manx Ventures, and the recently acquired Payment Assist. Advances grew 3.5% to £176.2m, supported by resilient demand in short-term lending, SME finance, and automotive point-of-sale credit. The Group maintains a solid CET1 capital ratio of 12.2% and £74m in liquidity, positioning it well for future expansion. Strategic priorities include optimising liquidity through dual banking licences, scaling Payment Assist (already serving over 1m customers and 7,000 garages), and launching innovative products such as the Finu overdraft app. Management also outlined growth opportunities in UK insurance broking, premium finance, and European expansion, with a consumer credit licence application underway in Ireland. Conister Bank continues to leverage its UK and Isle of Man deposit bases to fund growth and support acquisitions, while Manx Ventures pursues strategic equity stakes in resilient lending businesses. The Group reiterated its focus on margin expansion, efficiency, and shareholder value creation, with further M&A, dividends, and potential IPOs under review. With increasing returns on equity, strong customer demand for flexible credit, and a robust capital position, management believes the company remains undervalued and well placed to deliver sustainable growth.

Ebiquity PLC (AIM: EBQ) delivered its Interim 2025 results, highlighting resilient performance despite challenging global market conditions. Group revenue was flat at £37.9m, but disciplined cost management and operational improvements drove an 11% increase in adjusted operating profit to £2.6m, with margins improving to 6.8%. Strong cash generation saw adjusted cash from operations rise 77% to £4.6m, positive free cash flow of £0.7m, and net debt reduced to £15m. Growth was underpinned by exceptional 43% global contract compliance growth, including a 124% surge in the UK & Ireland, and 14% regional revenue growth. North America remained the weakest region, with revenue down 16% and an £8.3m goodwill impairment, though leadership changes, restructuring, and new AI-driven solutions aim to position the business for recovery. Ebiquity continues to invest in its transformation strategy, leveraging proprietary AI technology and its unique global dataset to enhance marketing effectiveness, compliance, and governance services. With over 75% of the world’s top 100 advertisers as clients, the company remains confident in delivering sustainable growth, improved margins, and stronger shareholder value as markets stabilize.

Quadrise PLC (AIM:QED) delivered its final results for the year ending 30 June 2025, highlighting steady progress towards commercialization of its patented emulsion fuel technologies designed to decarbonize shipping and heavy industry. Non-Executive Chairman Andy Morrison and the newly appointed CEO, Peter Borup, outlined a strengthened strategic and financial position, underpinned by a £5.9m cash balance following January’s fundraise. The company reported a £3m loss, in line with prior years, but reaffirmed funding is sufficient to reach revenue generation, positive cash flow, and profitability. Operational highlights included advancing its flagship Antwerp marine project with MSC and Cargill, a successful 50MW power plant trial in Panama, and progress with OCP in Morocco and Valkor in Utah. Quadrise continues to expand its BioMSAR and BioMSAR Zero product slate, aligned with tightening IMO and EU emissions regulations, positioning its fuels as competitive transition solutions delivering cost savings and significant CO₂ and NOx reductions. The management emphasized a stronger development pipeline, new sector expertise hires, and a clear focus on executing multiple parallel trials to accelerate adoption across global bunker hubs including Antwerp, Panama, Morocco, and Singapore. With a future-proofed technology portfolio and strong regulatory tailwinds, Quadrise is poised to transition from R&D to commercialization, targeting near-term revenue opportunities in marine fuels, utilities, and heavy industry, while building long-term growth through strategic partnerships and licensing agreements.

Genincode PLC (AIM: GENI) announced interim results showing 15% revenue growth to £1.6m, with full-year guidance of around 25% to £3.3m, improved gross margins of 53%, and a tightly managed loss of £2m with £2.4m in cash reserves, as the company advances its strategy in precision genetics for cardiovascular disease prevention and cancer risk assessment. The group is scaling its polygenic risk score (PRS) tests in cardiovascular medicine, with US clinical adoption accelerating as active ordering sites doubled from 20 to 40 clinics in H1 and are on track to exceed 60 by year-end, supported by Medicare reimbursement for Cardio InCode and ongoing FDA de novo review, with additional clinical data to be submitted in early 2026. Management confirmed advanced negotiations with potential US and international commercial partners, which could enable large-scale distribution. In the UK, Genincode continues to support the NHS’s 10-year prevention plan for heart disease, having delivered over 3,000 tests and identified hundreds of high-risk patients, although the company is pushing for faster adoption; in Europe, steady growth is being delivered across Spain, Italy, and Germany. Beyond cardiovascular, the company’s ROCA test for ovarian cancer surveillance has gained traction, with NHS trust adoption and international demand, marking it as the only globally approved test in this space, while ThromboInCode is due to launch in the UK and US within months, expanding the portfolio. Supported by a strong IP position, globally recognised publications, and harmonised AI-driven systems across the US, UK, and EU, Genincode is positioned to capitalise on its 17 years of development in polygenic testing, with upcoming landmark papers expected to reinforce its leadership in genetic risk assessment. Looking ahead, management emphasised revenue acceleration, margin expansion, and the medium-term objective of achieving breakeven, with growth underpinned by strategic partnerships, regulatory milestones, and international market expansion.

EJF Investments plc, the London-listed investment trust managed by EJF Capital, delivered its inaugural investor presentation highlighting performance, strategy, and outlook. The trust, launched in 2017, targets regulated debt opportunities in the U.S. banking and insurance sectors, focusing on small community banks and emerging credit risk transfer (CRT) structures. Over eight years, the portfolio has achieved an annualised return of over 8%, underpinned by consistent dividend payments and resilient performance through market cycles, including COVID-19 and recent U.S. regional bank failures. For the six months to June 2025, the portfolio generated an 8% return on underlying assets, despite FX headwinds impacting reported results. Net assets were supported by disciplined debt management, including refinancing ZDP shares, while shareholder alignment remains strong with EJF Capital and affiliates holding c.26% of ordinary shares and reinvesting management fees directly into the trust. The portfolio is diversified across bank and insurance subordinated debt (c.70%), recurring CDO management fee income, and a growing allocation to CRT transactions, where EJF has established a leading position with smaller U.S. banks. CRT exposure, currently 8%, is expected to rise to 20–25% of gross assets, offering mid-teens yields with bespoke structures and regulator-backed risk transfer. Looking ahead, management sees a favourable environment driven by U.S. bank refinancing needs, ongoing M&A among community banks, and a steepening yield curve supportive of margins. Initiatives to narrow the share price discount, including a tender offer and share buybacks, are underway, while management continues to target steady income, strong risk-adjusted returns, and long-term NAV growth.

Arecor Therapeutics PLC, a clinical-stage biopharmaceutical company focused on diabetes and cardiometabolic diseases, presented its interim results for the six months ended 30 June 2025, outlining strong progress across its proprietary pipeline and partnerships. The company highlighted its lead asset AT278, a highly concentrated, ultra-rapid acting insulin, positioned to transform automated insulin delivery (AID) systems. Arecor recently entered a co-development partnership with Sequel MedTech to advance AT278 into a Phase 2 clinical study, targeting a U.S. market opportunity of c.$2.9 billion for high-need diabetes patients. The company also announced a royalty financing agreement with Ligand Pharmaceuticals, securing $11 million (with $7 million upfront) linked to existing partnered assets, extending Arecor’s cash runway to H1 2027. This strengthens the balance sheet and provides flexibility to accelerate development and business development opportunities. Beyond its insulin franchise, Arecor is advancing an oral peptide delivery platform, initially targeting GLP-1 therapies, aiming to significantly improve bioavailability and expand patient access in the fast-growing obesity and diabetes markets. The platform addresses a major unmet need and is expected to attract significant pharma interest, given accelerating deal-making in this field. Financial highlights showed stable revenues of £2m, a reduction in SG&A expenses from the planned wind-down of Tetris Pharma, and a strengthened cash position post-financing. The company continues to partner with global leaders including Eli Lilly, Medtronic, and Sky Bioscience, validating its Arestat technology platform and licensing model with potential milestone and royalty upside. Looking ahead, Arecor is focused on progressing AT278 into Phase 2, advancing its oral peptide platform, and leveraging its strategic partnerships to drive value creation. Management reaffirmed its ambition to deliver transformational therapies in diabetes and obesity, strengthen shareholder value, and capture long-term growth opportunities.

Venture Life Group PLC (AIM: VLG) reported a strong set of interim results for the six months to June 2025, showcasing significant revenue growth, margin improvement, and a strengthened financial position. Group revenue rose 43% to £15.4m, supported by the full integration of Health & Her, with organic growth of 12.5%, while gross profit increased 50% to £6.6m and gross margins improved to 43.1%. Adjusted EBITDA advanced 33% to £1.8m, reflecting higher marketing investment to accelerate long-term growth across its consumer healthcare brands. Post-period, the disposal of its CDMO operations generated €65m in proceeds, leaving the company debt-free with £34m net cash and more than £80m in total firepower for strategic acquisitions. Core brands delivered strong momentum: Balance Active grew 24%, Health & Her and the newly launched Health & Him delivered 38% growth, while UK sales rose 13% and international revenue grew 11%. Expansion was driven by innovation, new product launches, and wider distribution across Boots, Superdrug, Holland & Barrett, and CVS in the US, alongside digital campaigns and healthcare professional endorsement. Management confirmed it is actively divesting its oral care brands to sharpen focus on higher-margin categories such as women’s and men’s health, energy management, and ENT, reinforcing its strategy as a pure-play consumer healthcare platform. Strategic priorities include leveraging an omnichannel model, embedding digital and AI capabilities, pursuing M&A with strict margin and return criteria, and maintaining a “#1 brand” mindset to secure category leadership. With cash reserves, strong retailer partnerships, and a robust innovation pipeline, Venture Life is well positioned to deliver sustainable growth, targeting gross margins above 50% and EBITDA margins above 25% in the medium term. The Board emphasised confidence in long-term shareholder value creation, supported by resilient brand performance, disciplined capital allocation, and attractive acquisition opportunities.